Central nervous system (CNS) cancers remain among the most difficult diseases to treat in oncology, with limited therapeutic options, complex deliv...
Fluid overload remains one of the most complex and costly challenges in cardiorenal care, particularly for patients who no longer respond to conventional d...
As pharmaceutical companies continue to face high attrition rates, rising development costs and increasingly complex clinical datasets, the industry is sea...
As biologics manufacturing operations become increasingly complex, biopharma companies are under growing pressure to improve efficiency, strengthen...
Regenerative medicine is entering a pivotal phase, shifting from long-standing scientific promise toward practical clinical application. BioRestorative The...
In this exclusive BioPharma Boardroom interaction, Thierry Van Nieuwenhove, CEO of Quotient Sciences, explores why nearly 90% of drug candidates fail and w...
From a basement-born idea to a publicly traded biotech advancing late-stage clinical trials, Lew Bender’s journey reflects both scientific persistenc...
As the antibody–drug conjugate (ADC) landscape rapidly evolves, the industry is moving beyond traditional cytotoxic payloads and antibody-first devel...
In this BioPharma Boardroom interview, Steven Quay, Founder and CEO of Atossa Therapeutics, outlines the scientific rationale behind developing (Z)-endoxif...
As artificial intelligence becomes increasingly embedded in formulation science and early clinical planning, the industry faces a dual challenge: accelerat...
As life sciences companies scale biologics, advanced therapies, and personalized medicines, sustainability has moved from aspiration to operational imperat...
Under the leadership of Joel Latham, Incannex Healthcare is advancing a differentiated pipeline of cannabinoid- and psychedelic-based thera...
In this BioPharma Boardroom interview, Jason Causon, Senior Technical Product Manager for Accurate Mass Platforms at SCIEX, explores how multiomi...
Drug delivery is entering a period of rapid reinvention, driven as much by analytical innovation as by molecular design. In this BioPharma BoardRoo...
© 2026 Biopharma Boardroom. All Rights Reserved.
